A systematic review and economic evaluation of the use of tumour necrosis factor-alpha (TNF-α) inhibitors, adalimumab and infliximab, for crohn's disease

Health Technology Assessment

Volumn 15, Issue 6, 2011, Pages 1-250

  Dretzke, J ^a   Edlin, R ^b   Round, J ^b   Connock, M ^a   Hulme, C ^b   Czeczot, J ^a   Fry Smith, A ^a   McCabe, C ^b   Meads, C ^c  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b UNIVERSITY OF LEEDS   (United Kingdom)

^c QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; AMINOSALICYLIC ACID DERIVATIVE; ANTIBIOTIC AGENT; AZATHIOPRINE; BUDESONIDE; C REACTIVE PROTEIN; CORTICOSTEROID; CYCLOSPORIN A; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; METRONIDAZOLE; PLACEBO; TACROLIMUS; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ABDOMINAL SURGERY; ABSCESS; ANAPHYLACTIC SHOCK; ANUS FISTULA; BACTERIAL INFECTION; BUDGET; CLINICAL EFFECTIVENESS; COLITIS; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; CROHN DISEASE; CROHN DISEASE ACTIVITY INDEX; CYTOMEGALOVIRUS INFECTION; CYTOPENIA; DELAYED HYPERSENSITIVITY; DEMYELINATING DISEASE; DISEASE SEVERITY; DIZZINESS; DOSAGE SCHEDULE COMPARISON; DRUG COST; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG ERUPTION; DRUG FATALITY; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; ECONOMIC EVALUATION; EXTRAPULMONARY TUBERCULOSIS; FLUSHING; HEALTH CARE COST; HEALTH CARE UTILIZATION; HEART FAILURE; HEPATITIS B; HOSPITALIZATION; HUMAN; INFECTION; INFLAMMATORY BOWEL DISEASE QUESTIONNAIRE; INJECTION SITE BURNING; INJECTION SITE CONTUSION; INJECTION SITE IRRITATION; INJECTION SITE PRURITUS; INJECTION SITE RASH; INJECTION SITE REACTION; JAUNDICE; LOADING DRUG DOSE; LOW DRUG DOSE; LUPUS LIKE SYNDROME; LYMPHOMA; MAINTENANCE THERAPY; MALIGNANT NEOPLASTIC DISEASE; META ANALYSIS; MORTALITY; MULTIPLE SCLEROSIS; MYCOSIS; NAUSEA; OPPORTUNISTIC INFECTION; OPTIC NEURITIS; PERIANAL DISEASE ACTIVITY INDEX; PNEUMOCYSTOSIS; PNEUMONIA; PREVALENCE; PROGNOSIS; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECOMMENDED DRUG DOSE; RECTOVAGINAL FISTULA; RELAPSE; REMISSION; REVIEW; SEPSIS; SIDE EFFECT; SINUSITIS; STOMACH PAIN; SYSTEMATIC REVIEW; THORAX PAIN; TOXIC HEPATITIS; TUBERCULOSIS; UNITED KINGDOM; UPPER RESPIRATORY TRACT INFECTION;

ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; COST-BENEFIT ANALYSIS; CROHN DISEASE; DECISION SUPPORT TECHNIQUES; GREAT BRITAIN; HUMANS; MODELS, ECONOMIC; QUALITY-ADJUSTED LIFE YEARS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 79951639158     PISSN: 13665278     EISSN: None     Source Type: Journal    
DOI: 10.3310/hta15060     Document Type: Review

References (118)

1. National Institute for Health and Clinical Excellence. Guidance on the use of infliximab for Crohn's disease. Technology Appraisal No. 40. 2002. URL: www.nice.org.uk/nicemedia/pdf/ NiceCROHNS40GUIDANCE.pdf (accessed October 2007).
2. Rutgeerts P, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, et al. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. Gastroenterology 2004;126:402-13.
3. Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, et al. Maintenance infliximab for Crohn's disease: The ACCENT I randomised trial. Lancet 2002;359:1541-9.
4. ®). Submission to the National Institute for Health and Clinical Excellence. Maidenhead: Abbott Laboratories Ltd.; 2007: 1-98.
5. Clark W, Raftery J, Song F, Barton P, Cummins C, Fry-Smith A, et al. Systematic review and economic evaluation of the effectiveness of infliximab for the treatment of Crohn's disease. Health Technol Assess 2003;7(3).
6. Marshall J, Blackhouse G, Goeree R, Brazier N, Irvine E, Faulkner L, et al. Infliximab for the treatment of Crohn's disease: a systematic review and cost-utility analysis. Technology report no 24. Ottawa: Canadian Coordinating Office for Health Technology Assessment; 2002.
7. Jaisson-Hot I, Flourie B, Descos L, Colin C. Management for severe Crohn's disease: a lifetime cost-utility analysis. Int J Technol Assess Health Care 2004;20:274-9.
8. Jewell D. Crohn's disease. Medicine 1998;26:87-92.
9. Carter MJ, Lobo AJ, Travis SP, on behalf of the IBD section of the British Society of Gastroenterology. Guidelines for the management of inflammatory bowel disease in adults. Gut 2004;53(Suppl. 5):V1-V16.
10. Hanauer SB, Sandborn W. Management of Crohn's disease in adults. Am J Gastroenterology 2001;96:635-43.
11. Jenkins HR. Inflammatory bowel disease. Arch Dis Child 2001;85:435-7.
12. Henriksen M, Jahnsen J, Lygren I, Aadland E, Schulz T, Vatn MH, et al. Clinical course in Crohn's disease: results of a five-year population-based follow-up study (the IBSEN study). Scand J Gastroenterol 2007;42:602-10.
13. Vermeire S, Van Assche G, Rutgeerts P. Review article: altering the natural history of Crohn's disease-evidence for and against current therapies. Aliment Pharmacol Ther 2006;25:3-12.
14. Baumgart DC, Sandborn WJ. Inflammatory bowel disease: clinical aspects and established and evolving therapies. Lancet 2007;369:1641-57.
15. Hanauer SB, Meyers S. Managment of Crohn's disease in adults. Am J Gastroenterol 1997;92:559-65.
16. Irvine EJ. Usual therapy improves perianal Crohn's disease as measured by a new Disease Activity Index. J Clin Gastroenterol 1995;20:27-32.
17. Loftus EV. Clinical epidemiology of inflammatory bowel disease: incidence, prevalence, and environmental influences. Gastroenterology 2004;126:1504-17.
18. Meuwis MA, Fillet M, Chapelle JP, Malaise M, Louis E, Merville MP. New biomarkers of Crohn's disease: serum biomarkers and development of diagnostic tools. Expert Rev Mol Diagn 2008;8:327-37.
19. Knigge KL. Inflammatory bowel disease. Clin Cornerstone 2002;4:49-60.
20. Gurudu S, Fiocchi C, Katz JA. Inflammatory bowel disease. Best Pract Res Clin Gastroenterol 2002;16:77-90.
21. Silverberg MS, Satsangi J, Ahmad T, Arnott ID, Bernstein CN, Brant SR, et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: Report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol 2005;19(Suppl. A):5-36.
22. Louis E, Collard A, Oger AF, Degroote E, Aboul Nasr El Yafi FA, Belaiche J. Behaviour of Crohn's disease according to the Vienna classification: changing pattern over the course of the disease. Gut 2001;49:777-82.
23. Cosnes J, Cattan S, Blain A, Beaugerie L, Carbonnel F, Parc R, et al. Long-term evolution of disease behavior of Crohn's disease. Inflamm Bowel Dis 2002;8:244-50.
24. Felley C, Mottet C, Juillerat P, Froehlich F, Burnand B, Vader JP, et al. Fistulizing Crohn's disease. Digestion 2005;71:26-8.
25. Munkholm P, Langholtz E, Davidsen M, Binder V. Disease activity courses in a regional cohort of Crohn's disease patients. Scand J Gastroenterol 1995;30:699-706.
26. Silverstein MD, Loftus EV, Sandborn WJ, Tremaine WJ, Feagan BG, Nietert PJ, et al. Clinical course and costs of care for Crohn's disease: Markov model analysis of a population-based cohort. Gastroenterology 1999;117:49-57.
27. Russel MGVM. Changes in the incidence of inflammatory bowel disease: what does it mean? Eur J Int Med 2000;11:191-6.
28. Hanauer SB. Inflammatory bowel disease: epidemiology, pathogenesis, and therapeutic opportunities. Inflamm Bowel Dis 2006;12(Suppl. 1):S3-S9.
29. Ehlin AGC, Montgomery SM, Ekbom A, Pounder RE, Wakefield AJ. Prevalence of gastrointestinal diseases in two British national birth cohorts. Gut 2003;52:1117-21.
30. Rubin GP, Hungin APS, Kelly PJ, Ling J. Inflammatory bowel disease: epidemiology and management in an English general practice population. Aliment Pharmacol Ther 2000;14:1553-9.
31. National Association for Colitis and Crohn's Disease. Inflammatory bowel disease basics. 2004. URL: http://nacc.org.uk/content/ibd.asp (accessed 25 April 2007).
32. Shivananda J, Lennard-Jones J, Logan R, Fear N, Price A, Carpenter L, et al. Incidence of inflammatory bowel disease across Europe: is there a difference between north and south? Results of the European collaborative study on inflammatory bowel disease (EC-IBD). Gut 1996;39:690-7.
33. Stone MA, Mayberry JF, Baker R. Prevalence and management of inflammatory bowel disease: a cross-sectional study from central England. Eur J Gastroenterol Hepatol 2003;15:1275-80.
34. Yapp TR, Stenson R, Thomas GAO, Lawrie BW, Williams GT, Hawthorne AB. Crohn's disease incidence in Cardiff from 1930: an update for 1991-1995. Eur J Gastroenterol Hepatol 2000;12:907-11.
35. National Association for Colitis and Crohn's Disease. Information sheets and drug treatment information. 2004. URL: www.nacc.org.uk/content/services/infoSheets.asp (accessed 7 November 2007).
36. Blondel-Kucharski F, Chircop C, Marquis P, Cortot A, Baron F, Gendre J, et al. Health-related quality of life in crohn's disease: a prospective longitudinal study in 231 patients. Am J Gastroenterol 2001;96:2915-20.
37. Bassi A, Dodd S, Williamson P, Bodger K. Cost of illness of inflammatory bowel disease in the UK: a single centre retrospective study. Gut 2004;53:1471-8.
38. Sostegni R, Daperno M, Scaglione N, Lavagna A, Rocca R, Pera A. Review article: Crohn's disease: monitoring disease activity. Aliment Pharmacol Ther 2003;17(Suppl. 2):11-17.
39. Best WR, Becktel JM, Singleton JW, Kern F jr. Development of a Crohn's Disease Activity Index. National Co-operative Crohn's disease study. Gastroenterology 1976;70:439-44.
40. Yoshida EM. The Crohn's Disease Activity Index, its derivatives and the Inflammatory Bowel Disease Questionnaire: a review of instruments to assess Crohn's disease. Can J Gastroenterol 1999;13:65-73.
41. Sandborn WJ, Feagan BG, Hanauer SB, Lochs H, Lofberg R, Modigliani R, et al. A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn's disease. Gastroenterology 2002;122:512-30.
42. Best WR. Predicting the Crohn's Disease Activity Index from the Harvey-Bradshaw Index. Inflamm Bowel Dis 2006;12:304-10.
43. Irvine EJ, Feagan BG, Rochon J, Archambault A, Fedorak RN, Groll A, et al. Quality of Life: a valid and reliable measure of therapeutic efficacy in the treatment of inflammatory bowel disease. Gastroenterology 1994;106:287-96.
44. Mary JY, Modigliani R. Development and validation of an endoscopic index for the severity for Crohn's disease: a prospective multicentre study. Gut 1989;30:983-9.
45. Hyams J, Crandall W, Kugathasan S, Griffiths A, Olson A, Johanns J, et al. Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children. Gastroenterology 2007;132:863-73.
46. Baldassano R, Braegger CP, Escher JC, DeWoody K, Hendricks DF, Keenan GF, et al. Infliximab (REMICADE) therapy in the treatment of pediatric Crohn's disease. Am J Gastroenterol 2003;98:833-8.
47. Joint Formulary Committee. British National Formulary. London: British Medical Association and Royal Pharmaceutical Society of Great Britain; 2008.
48. Loftus EV, Schoenfeld P, Sandborn WJ. The epidemiology and natural history of Crohn's disease in population-based patient cohorts from North America: a systematic review. Aliment Pharmacol Ther 2002;16:51-60.
49. Royal College of Physicians. UK IBD Audit 2006. National Results for the Organisation & Process of IBD Care in the UK. 2006. URL: www.rcplondon.ac.uk/clinical-standards/ceeu/ Current-work/IBD/Pages/1st-Round.aspx (accessed November 2010).
50. Schreiber S, Rutgeerts P, Fedorak RN, Khaliq-Kareemi M, Kamm MA, Boivin M, et al. A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease. Gastroenterology 2005;129:807-18.
51. Calabrese L. The yin and yang of tumor necrosis factor inhibitors. Cleve Clin J Med 2006;73:251-6.
52. European Medicines Agency. Summary of Product Characteristics (Humira). URL: www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/ human/000481/WC500050870.pdf (accessed November 2010).
53. European Medicines Agency. Summary of Product Characteristics (Remicade). URL: www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/ human/000240/WC500050888.pdf (accessed November 2010).
54. Centocor I. Medication Guide Remicade. 2007.URL: www.remicade.com/remicade/assets/ Med_Guide.pdf (accessed 10 October 2007).
55. Abbott Laboratories. Important Safety Information Humira. 2007. URL: www.humira.com (accessed 10 October 2007).
56. Han PD, Cohen RD. Managing immunogenic responses to infliximab. Drugs 2004;64:1767-77.
57. Targan S, Hanauer SB, van Deventer SJH, Mayer L, Present DH, Braakman T, et al. A short term study of chimeric monoclonal antibody cA2 to tumour necrosis factor alpha for Crohn's disease. N Engl J Med 1997;337:1029-35.
58. Rutgeerts P, D'Haens G, Targan S, Vasiliauskas E, Hanauer SB, Present DH, et al. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's Disease. Gastroenterology 1999;117:761-9.
59. Farrell RJ, Alsahli M, Jeen Y-T, Falchuk KR, Peppercorn MA, Michetti P. Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: A randomized controlled trial. Gastroenterology 2003;124:917-24.
60. Lemann M, Mary J, Duclos B, Veyrac M, Dupas J, Delchier JC, et al. Infliximab Plus azathioprine for steroid-dependent Crohn's disease patients: a randomized placebocontrolled trial. Gastroenterology 2006;130:1054-61.
61. Hommes DW, Baert F, Van Assche G, Caenepeel F, Vergauwe P, Tuynman H, et al. Management of recent onset Crohn's disease: a controlled, randomised trial comparing step-up and top-down therapy (Abstract). Gastroenterology 2005;129:371.
62. Present DH, Rutgeerts P, Targan S, Hanauer SB, Mayer L, van Hogezand Rea. Infliximab for the treatment of fistulae in patients with Crohn's disease. N Engl J Med 1999;340:1398-405.
63. Hanauer SB, Sandborn WJ, Rutgeerts P, Fedorak RN, Lukas M, MacIntosh D, et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: The CLASSIC-I trial. Gastroenterology 2006;130:323-32.
64. Sandborn WJ, Rutgeerts P, Enns R, Hanauer SB, Colombel JF, Panaccione R, et al. Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. Ann Intern Med 2007;146:829-38.
65. Sands BE, Anderson FH, Bernstein CN, Chey WY, Feagan BG, Fedorak RN, et al. Infliximab maintenance therapy for fistulizing Crohn's Disease. N Engl J Med 2004;350:876-85.
66. Sandborn WJ, Hanauer SB, Rutgeerts PJ, Fedorak RN, Lukas M, Macintosh DG, et al. Adalimumab for maintenance treatment of Crohn's Disease: Results of the CLASSIC II Trial. Gut 2007;56:1232-9.
67. Colombel J, Sandborn WJ, Rutgeerts P, Enns R, Hanauer SB, Panaccione R, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's Disease: The CHARM Trial. Gastroenterology 2007;132:52-65.
68. D'Haens G, van Deventer S, van Hogezand R, Chalmers D, Kothe C, Baert F. Endoscopic and histological healing with infliximab anti-tumour necrosis factor antibodies in Crohn's disease. Gastroenterology 1999;116:1029-34.
69. Egger M, Davey Smith G, Altman DG. Systematic reviews in health care; meta-analysis in context. 2nd edition. London: BMJ Books; 2001.
70. Menter A, Feldman SR, Weinstein GD, Papp K, Evans R, Guzzo C, et al. A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis. J Am Acad Dermatol 2007;56:15-31.
71. Wu EQ, Yu A, Atanasov P, Tang J, Pollack P, Lomax K, et al. Lower disease activity and clinical remission are associated with reduced hospitalisation risk in Crohn's disease. ISPOR 12th Annual International Meeting, Arlington, VA, 19-23 May 2007.
72. Feagan B, Panaccione R, Sandborn W, D'Haens G, Schreiber S, Rutgeerts P, et al. An evaluation of adalimumab on the risk of hospitalisation in patients with Crohn's disease, data from CHARM. Digestive Disease Week (DDW), Washington, DC, 19-24 May 2007.
73. Behm BW, Bickston SJ. Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev 2008;1:CD006893.
74. Glenny AM, Altman DG, Song F, Sakarovitch C, Deeks JJ, D'Amico R. Indirect comparisons of competing interventions. Health Technol Assess 2005;9(26).
75. Sands BE, Blank MA, Patel K, Van Deventer SJ. Long-term treatment of rectovaginal fistulas in Crohn's disease: Response to infliximab in the ACCENT II study. Clin Gastroenterol Hepatol 2004;2:912-20.
76. Sands BE, Blank MA, Diamond RH, Barrett JP, Van Deventer SJ. Maintenance infliximab does not result in increased abscess development in fistulizing Crohn's disease: Results from the ACCENT II study. Aliment Pharmacol Ther 2006;23:1127-36.
77. Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006;295:2275-85.
78. Shoor S. Review: anti-tumor necrosis factor antibody therapy for rheumatoid arthritis increases risk for serious infection and malignancy. ACP J Club 2006;145:65.
79. Raval A, khavan-Toyserkani G, Brinker A, Avigan M. Brief communication: characteristics of spontaneous cases of tuberculosis associated with infliximab. Ann Intern Med 2007;147:699-702.
80. Ramos-Casals M, Brito-Zeron P, Munoz S, Soria N, Galiana D, Bertolaccini L, et al. Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases. Medicine (Baltimore) 2007;86:242-51.
81. Kwon HJ, Cote TR, Cuffe MS, Kramer JM, Braun MM. Case reports of heart failure after therapy with a tumor necrosis factor antagonist. Ann Intern Med 2003;138:807-11.
82. Socal MP, Vargas AP, Laporte EA, Costa AF, Picon PD. Progressive multifocal leukoencephalopathy induced by monoclonal antibodies- a systematic review: preliminary data. Poster presentation HTA conference, Montreal, QC, 2008.
83. Yamomoto M, Takahashi H, Wakasugi H, Sukawa Y, Saito M, Suzuki C, et al. Leukoencephalopathy during administration of etanercept for refractory rheumatoid arthritis. Mod Rheumatol 2007;17:72-4.
84. Su C, Lichtenstein G, Krok K, Brensinger CM, Lewis JD. A meta-analysis of the placebo rates of remission and response in clinical trials of active Crohn's disease. Gastroenterology 2004;126:1257-69.
85. Chang M, Chow S-C. Adaptive design methods in clinical trials - a review. Orphanet J Rare Dis 2008;3:11-36.
86. Breban M, Ravaud P, Claudepierre P, Baron G, Henry YD, Hudry C, et al. Maintenance of infliximab treatment in ankylosing spondylitis: results of a one-year randomized controlled trial comparing systematic versus on-demand treatment. Arthritis Rheum 2008;58:88-97.
87. Chen Y-F, Jobanputra P, Barton P, Jowett S, Bryan S, Clark W, et al. A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness. Health Technol Assess 2006;10(42).
88. Brodsky RA, Young NS, Antonioli E, Risitano AM, Schrezenmeier H, Schubert J, et al. Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria. Blood 2008;111:1840-7.
89. Drummond MF, Jefferson T. Guidelines for authors and peer reviewers of economic submissions to the BMJ. BMJ 1996;313:275-83.
90. Arseneau KO, Cohn SM, Cominelli F, Connors AFJ. Cost-utility of initial medical management for Crohn's disease perianal fistulae. Gastroenterology 2001;120:1640-56.
91. Marshall JK, Blackhouse G, Goeree R, Brazier N, Irvine EJ, O'Brien BJ. Clinical and economic assessment: infliximab for the treatment of Crohn's disease. Technology overview no. 8. Ottawa: Canadian Coordinating Office for Health Technology Assessment; 2002.
92. Gregor J, McDonald JWD, Klar N, Wall R, Atkinson K, Lamba B. An evaluation of utility measure in Crohn's disease. Inflamm Bowel Dis 1997;3:265-76.
93. National Institute of Health and Clinical Excellence. Guide to the methods of technology appraisal. London: NICE; 2008.
94. Organisation for economic co-operation and development. Purchasing Power Parities (PPP). URL: www.oecd.org/std/ppp (accessed November 2007).
95. Office for National Statistics. Retail Prices Index: annual index numbers of retail prices 1948-2009 (RPI) (RPIX). URL: www.statistics.gov.uk/statbase/tsdataset. asp?vlnk=7172&More=N&All=Y (accessed November 2007).
96. ® in the treatment of Crohn's disease in the United Kingdom. Submission to the National Institute for Health and Clinical Excellence. 2007: 1-67.
97. Wolters FL, Russel MG, Sijbrandij J, Schouten L, Odes S, Riis L, et al. Crohn's disease: increased mortality 10 years after diagnosis in a Europe-wide population based cohort. Gut 2006;55:510-18.
98. Jess T, Riis L, Vind I, Winther KV, Borg S, Binder V, et al. Changes in clinical characteristics, course and prognosis of inflammatory bowel disease during the last 5 decades: a populationbased study from Copenhagen, Denmark. Inflamm Bowel Dis 2007;13:481-9.
99. Woolacott N, Bravo Vergel Y, Hawkins N, Kainth A, Khadjesari Z, Misso K, et al. Etanercept and infliximab for the treatment of psoriatic arthritis: a systematic review and economic evaluation. Health Technol Assess 2006;10(31).
100. Casellas F, Arenas JI, Baudet JS, Fabregas S, Garcia N, Gelabert J, et al. Impairment of healthrelated quality of life in patients with inflammatory bowel disease: a Spanish multicenter study. Inflamm Bowel Dis 2005;11:488-96.
101. Dolan P, Gudex C, Kind P, Williams A, Centre for Health Economics, University of York. A social tariff of EuroQol: results from a UK general population survey. Centre for Health Economics discussion paper 138. 1995.
102. British Medical Association and Royal Pharmaceutical Society of Great Britain. British national formulary. No. 53, March 2007. London: BMA and RPS; 2007.
103. Curtis L, Netten A. Unit costs of of health and social care. Canterbury: Personal Social Services Research Unit; 2006: pp. 1-230.
104. National Institute of Health and Clinical Excellence. Guide to the methods of technology appraisal. London: NICE; 2004.
105. Department of Health. NHS reference costs 2005-06. 2006. URL: www.dh.gov.uk/en/ publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_062884 (accessed June 2008).
106. Rosenbaum PL, Saigal S. Measuring health-related quality of life in paediatric populations: conceptual issues. In: B Spilker, editor. Quality of life and pharmacoeconomics in clinical trials. 2nd edn. Philadelphia: Lippincott-Raven; 1996: 785-91.
107. Harris M, Buttterworth G. Developmental psychology: A student's handbook. Hove: Psychology Press; 2002.
108. Matza LS, Swensen AR, Flood EM, Secnik K, Leidy NK. Assessment of health-related quality of life in children: a review of conceptual, methodological, and regulatory issues. Value Health 2004;7:79-92.
109. Fox-Rusby J, Parker M. Culture and the measurement of health-related quality of life. Eur Rev Appl Psychol 1995;45:257-63.
110. Petrou S, Henderson J. Preference-based approaches to measuring the benefits of perinatal care. Birth 2003;30:217-26.
111. Department of Health. NHS reference costs 2006-07.2008. URL: www.dh.gov.uk/en/ Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_082571 (accessed June 2008).
112. National Institute of Health and Clinical Excellence. Use of tumour necrosis factor alpha (TNF a) inhibitors (adalimumab, and infliximab [review]) for Crohn's disease (review of TA40). 2010. URL: http://guidance.nice.org.uk/TA187 (accessed November 2010).
113. TheyWorkForYou.com. NHS: Drugs. Health. Written answers and statements, 12 July 2007. 2007. URL: www.theyworkforyou.com/wrans/?id=2007-07-12b.149489.h&s=NHS+drug+budget+2004+2005+2006-01-01.2008-01-01#g149489.r0 (accessed 29 October 2007).
114. Moore TJ, Cohen MR, Furberg CD. Serious adverse drug events reported to the Food and Drug Administration, 1998-2005. Arch Intern Med 2007;167:1752-9.
115. The Information Centre. Hospital Prescribing, 2006: England. Statistical Bulletin IC. London: The Information Centre; 2007: 1-24.
116. Hanauer SB. Turning traditional treatment strategies on their heads: Current evidence for 'step-up' versus 'top-down'. Rev Gastroenterol Disord 2007;7(Suppl. 2):S17-S22.
117. Schreiber S, Khaliq-Kareemi M, Lawrance IC, Ostergaard Thomsen O, Hanauer SB, McColm J, et al. Maintenance therapy with certolizumab pegol for Crohn's disease. N Engl J Med 2007;357:239-50.
118. Winter TA, Wright J, Ghosh S, Jahnsen J, Innes A, Round P. Intravenous CDP870, a PEGylated Fab' fragment of a humanized antitumour necrosis factor antibody, in patients with moderate-to-severe Crohn's disease: an exploratory study. Aliment Pharmacol Ther 2004;20:1337-46.